DOCSLIB.ORG

(Ondansetron Hydrochloride Dihydrate) Solution for Injection 2Mg/Ml, 4Ml Ampoules (5) Teva

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Ondansetron Hydrochloride Dihydrate) Solution for Injection 2Mg/Ml, 4Ml Ampoules (5) Teva Teva Pharmaceutical Teva Pharmaceutical ondansetron Works Private Industries Ltd., 5 (ondansetron 2mg/ml, 06.06.2013 3166 Ondansetron-Teva solution for injection Limited Company, H- Hungary A04AA01 12554 PoM Basel str., P.O. Box hydrochloride 4ml ampoules (5) 06.06.2018 2100 Godollo, 3190, Petach Tikva, dihydrate) Tancsics Mihaly ut 82 49131, Israel Teva Pharmaceutical ondansetron Pliva Hrvatska d.o.o., Industries Ltd, 5 Basel (ondansetron 2mg/ml, Prilaz baruna 06.06.2013 3167 Ondansetron-Teva solution for injection Croatia A04AA01 12555 PoM str., P.O. Box 3190, hydrochloride 2ml ampoules (5) Filipovica 25, Zagreb 06.06.2018 Petah Tikva, 49131, dihydrate) 10000 Israel Teva Pharmaceutical ondansetron Pliva Hrvatska d.o.o., Industries Ltd, 5 Basel (ondansetron 2mg/ml, Prilaz baruna 06.06.2013 3168 Ondansetron-Teva solution for injection Croatia A04AA01 12556 PoM str., P.O. Box 3190, hydrochloride 4ml ampoules (5) Filipovica 25, Zagreb 06.06.2018 Petah Tikva, 49131, dihydrate) 10000 Israel L.Molteni & C. Dei L.Molteni & C. Dei F.lli Alitti Societa di F.lli Alitti Societa di 2mg/ml, morphine Esercizio S.p.A, S. S. 03.04.2017 Esercizio S.p.A, S. S. 3169 Oramorph solution oral 100ml glass bottle and Italy N02AA01 16579 PoM/UC (morphine sulfate) 67, Localita 03.04.2022 67, Localita measuring cup Granatieri, Scandicci, Granatieri, Scandicci, 50018 50018, Italy L.Molteni & C. Dei L.Molteni & C. Dei F.lli Alitti Societa di F.lli Alitti Societa di 20mg/ml, morphine Esercizio S.p.A, S. S. 08.08.2017 Esercizio S.p.A, S. S. 3170 Oramorph solution oral 20ml glass vial with Italy N02AA01 16911 PoM/UC (morphine sulfate) 67, Localita 08.08.2022 67, Localita dropper Granatieri, Scandicci, Granatieri, Scandicci, 50018 50018, Italy 681 Bayer Consumer Famar S.A.,National Care AG, Peter 14mg/ml, 05.06.2017 3171 Orasept phenol spray Road Athens-Lamia, Greece R02AA19 16735 OTC Merian-Strasse 84, 177ml plastic bottle 05.06.2022 Km 49, 19011 Avlona 4052 Basel, Switzerland Organon (Ireland) Ltd., Drynam Road, Swords, Co. Dublin - secondary packager, batch releaser (bulk Schering-Plough manufacturer, Central East AG, ganirelix (ganirelix solution for s/c 0,25mg/0,5ml, 0,5ml pre- primary packager - 29.07.2014 Weystrasse 20, P.O. 3172 Orgalutran Ireland H01CC01 12711/1 PoM acetate) injection filled syringes (5) Vetter Pharma- 23.07.2018 Box CH-6000 Fertigung GmbH & Lucerne 6, Co. KG, Switzerland Schutzenstrasse 87 and 99/101, D-88212 Ravensburg, Germany) N.V. Organon, Molenstraat 110, 5342 CC OSS-secondary packager, batch releaser (legal address - N.V. Organon, Schering-Plough Kloosterstraat 6, 5349 0.25mg/0.5ml (0.5mg/ml), Central East AG, ganirelix (ganirelix solution for s/c AB Oss, the 04.05.2015 3173 Orgalutran 0,5ml pre-filled syringes the Netherlands H01CC01 14458 PoM Weystrasse 20, 6000 acetate) injection Netherlands), Vetter 04.05.2020 (5) Lucerne 6, Pharma-Fertigung Switzerland GmbH & Co. KG, Schutzenstrasse 87 and 99/101, D-88212 Ravensburg, Germany- bulk manufacturer, primary packager 682 GM Pharmaceuticals GM Pharmaceuticals 120mg, 05.06.2017 3174 Orlip orlistat capsules Ltd, Phonichala 65, Georgia A08AB01 16738 PoM Ltd, Phonichala 65, in blister (30/3x10/) 05.06.2022 0165 Tbilisi 0165 Tbilisi, Georgia Medicus S.A., 10 Help S.A., Pedini Valaoritou str., GR amikacin (amikacin solution for 250mg/ml, 23.10.2017 3175 Orlobin Ioanninon, Ioannina, Greece J01GB06 17113 PoM 144 52, sulfate) injection/infusion glass vial (1) 23.10.2022 45500 Metamorphosis, Attika, Greece Belmedpreparaty Belmedpreparaty 500mg, 19.04.2016 RUE, 220007, Minsk, 3176 Ornidazole ornidazole tablets film-coated RUE, 220007, Minsk, Belarus P01AB03 15518 PoM in blister (10/1x10/) 19.04.2021 Fabritsius St., 30, Fabritsius St., 30 Belarus 500mg, "Rubicon" LLC, 62B, "Rubicon" LLC, 62B, 10.02.2017 3177 Ornimed ornidazole tablets film-coated in blister (10/1x10/, M. Gorky street, Belarus P01AB03 16422 PoM M. Gorky street, 10.02.2022 20/2x10/) 210002, Vitebsk 210002, Vitebsk 120mg, KRKA-RUS LLC, 50 KRKA d.d., Novo in blister (21/3x7/, Moskovskaya Str., 12.05.2016 mesto, Smarjeska 3178 Orsoten orlistat capsules Russia A08AB01 15579 PoM 21/1x21/, 42/6x7/, Istra, Moscow 12.05.2021 cesta 6, 8501 Novo 42/2x21/) Region,143500 Mesto, Slovenia PJSC "Technolog", PJSC "Technolog", Manuylskogo str. 8, Manuylskogo str. 8, diclofenac tablets gastro- 25mg, 05.10.2017 3179 Ortophen 20300 Ukraine M01AB05 17066 PoM 20300 (diclofenac sodium) resistant in blister (30/3x10/) 05.10.2022 Uman,Cherkassy Uman,Cherkassy region region, Ukraine 683 Tatchempharmpre- Tatchempharmpre- 25mg, paraty JSC, 420091 Ortophen diclofenac tablets gastro- paraty JSC, 420091 08.02.2017 3180 blister (30/3x10/, Russia M01AB05 13899/1 PoM Kazan, str. Tatpharm (diclofenac sodium) resistant Kazan, str. 30.09.2019 30/2x15/) Belomorskaya 260, Belomorskaya 260 Russia Pharmaceutical Pharmaceutical 25mg, Company "Zdorovye" Ortophen- diclofenac tablets gastro- Company "Zdorovye" 05.06.2017 3181 in blister (30/1x30/, Ukraine M01AB05 16743 PoM LLC, 61013, Kharkov, Zdorovye (diclofenac sodium) resistant LLC, 61013, Kharkov, 05.06.2022 30/3x10/) Shevchenko str., 22, Shevchenko str., 22 Ukraine Johnson & Johnson Janssen Cilag S.p.A., LLC, 121614, 100mg, Via C. Janssen, Borgo 18.12.2014 3182 Orungal itraconazole capsules Italy J02AC02 13905/1 PoM Moscow, Krylatskaya in blister (14/1x14/) San Michele, 04100 17.10.2019 str., 17, building 2, Latina Russia S.C. Slavia Pharm S.C. Rompharm S.R.L., Bd. Theodor Company S.R.L., 100mg, 07.03.2013 3183 Orunit itraconazole capsules Pallady No 44 C, Romania J02AC02 12232 PoM Ilfov, 075100 in blister (15) 07.03.2018 sector 3, Bucuresti, Otopeni, Str. Eroilor, 032266 No 1A, Romania Liqvor CJSC, 0089, 60mg/ml, Liqvor CJSC, 0089, Republic of 08.08.2017 Yerevan, str. 3184 OslaDex hydroxyethyl starch solution for infusion 100ml, 200ml, 500ml Yerevan, str. B05AA07 16880 PoM Armenia 08.08.2022 Kochinyan, 7/9, plastic pack Kochinyan, 7/9 Republic of Armenia Sandoz GmbH, amoxicillin Sandoz GmbH, powder for oral 250mg/5ml, 26.02.2016 Biochemiestrasse 10, 3185 Ospamox (amoxicillin Biochemiestrasse 10, Austria J01CA04 15392 PoM suspension 60ml glass bottle 26.02.2021 A-6250 Kundl, trihydrate) A-6250 Kundl Austria 684 Sandoz GmbH, amoxicillin Sandoz GmbH, powder for oral 125mg/5ml, 26.02.2016 Biochemiestrasse 10, 3186 Ospamox (amoxicillin Biochemiestrasse 10, Austria J01CA04 15393 PoM suspension 60ml glass bottle 26.02.2021 A-6250 Kundl, trihydrate) A-6250 Kundl Austria Gedeon Richter Polska Sp. z o.o., ul. Ks. J. Poniatowskiego 5, Grodzisk Mazowiecki, 05-825- Gedeon Richter PLC, alendronic acid batch releaser, 70mg, 19.12.2016 Gyomroi ut 19-21, 3187 Ostalon (alendronate tablets film-coated Gedeon Richter Poland M05BA04 16248 PoM in blister (4/1x4/) 19.12.2021 1103 Budapest, sodium trihydrate) Polska Sp. z o.o., ul. Hungary Graniczna 35, Grodzisk Mazowiecki, 05-825, Poland-bulk manufacturer, packager Pierre Fabre Pierre Fabre ossein- Medicament Medicament 830mg, 19.04.2016 3188 Osteogenon hydroxyapatite tablets film-coated Production, site France M05BX 15535 PoM Production, 45, place in blister (40/4x10/) 19.04.2021 compound Progipharm, Rue du Abel Gance, 92100 Lycee, 45500 Gien Boulogne, France Pharmathen International S.A., raloxifene Pharmathen S.A., 60mg, Industrial Park Sapes, 16.11.2016 3189 Ostiral (raloxifene tablets film-coated Greece G03XC01 15410/1 PoM Dervenakion 6, 15351 in blister (28/2x14/) Rodopi Prefecture, 09.03.2021 hydrochloride) Pallini, Attiki, Greece Block No 5, Rodopi 69300 685 Brupharmexport sprl, Rue de la Grotte, 14, B-1020, Brussels- 45.52mg/ml+ batch releaser, S.C. Brupharmexport sprl, phenazone, 11.38mg/ml, Rompharm Company 16.04.2015 Rue de la Grotte, 14, 3190 Otibru lidocaine (lidocaine solution (ear drops) Belgium N01BB52 14405 OTC 15ml plastic bottle- S.R.L., Ilfov, 75100 16.04.2020 B-1020, Brussels, hydrochloride) dropper Otopeni, Str. Eroilor, Belgium Nr. 1A, Romania - bulk manufacturer, packager Arpimed LLC, Arpimed LLC, Kotayk phenazone, Kotayk Marz, 40mg/g+10mg/g, 5g and Marz, Abovyan, 2nd Republic of 29.10.2014 3191 Oticaine lidocaine (lidocaine drops ear SO2DA 13948 OTC Abovyan, 2nd Micro- 15g plastic bottle Micro-District, 19 Armenia 29.10.2019 hydrochloride) District, 19 Building, Building Republic of Armenia Biocodex,1 avenue Biocodex,1 avenue Blaise Pascal, 60000 Blaise Pascal, 60000 phenazone, 40mg/g+10mg/g, Beauvais for 16.11.2017 Beauvais for 3192 Otipax lidocaine (lidocaine drops ear 15ml (16g) glass vial and France S02DA 17125 OTC Biocodex, 7 avenue 16.11.2022 Biocodex, 7 avenue hydrochloride) dropper Gallieni 94250 Gallieni 94250 Gentilly, France Gentilly, France S.C. Rompharm S.C. Rompharm phenazone, 40mg/g+10mg/g, Company S.R.L., Company S.R.L., 06.03.2017 3193 Otirelax lidocaine (lidocaine drops ear 15ml plastic bottle- Ilfov, 075100 Romania S02DA30 16452 OTC Ilfov, 075100 06.03.2022 hydrochloride) dropper Otopeni, Str. Eroilor, Otopeni, Str. Eroilor, Nr. 1A Nr. 1A, Romania Laboratoires Laboratoires Bouchara- Bouchara-Recordati rifamycin 26mg (20000IU)/ml, 10ml Recordati 68 Rue 24.12.2014 3194 Otofa drops ear France S02AA12 14165 PoM 68 Rue Marjolin (rifamycin sodium) glass bottle with dropper Marjolin 92300 24.12.2019 92300 Levallois Levallois Perret Perret, France 686 Laboratoires Bouchara- Recordati, Immeuble "le Wilson", 70 Laboratoires avenue du General de Bouchara-Recordati, Gaulle, 92800 26mg (20000IU)/ml, Immeuble "le rifamycin Puteaux- batch 10.04.2017 3195 Otofa drops ear 10ml glass bottle with France S02AA12 16609 PoM Wilson", 70 avenue (rifamycin
Load more

Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Crowdsourcing Analysis of Off-Label Intervention Usage in Amyotrophic Lateral Sclersosis
    CROWDSOURCING ANALYSIS OF OFF-LABEL INTERVENTION USAGE IN AMYOTROPHIC LATERAL SCLERSOSIS A Thesis Presented to The Academic Faculty by Benjamin I. Mertens In Partial Fulfillment of the Requirements for the Degree B.S. in Biomedical Engineering with the Research Option in the Wallace H. Coulter School of Biomedical Engineering Georgia Institute of Technology Spring 2017 1 ACKNOWLEDGEMENTS I would like to thank my research advisor, Dr. Cassie Mitchell, first and foremost, for helping me through this long process of research, analysis, writing this thesis and the corresponding article to be submitted for peer-reviewed journal publication. There is no way I could have done this, or written it as eloquently without her. Next, I would like to acknowledge Grant Coan, Gloria Bowen, and Nathan Neuhart for all helping me on the road to writing this paper. Lastly, I would like to thank Dr. Lena Ting for her consultation as the faculty reader. 2 TABLE OF CONTENTS Page ACKNOWLEDGEMENTS 2 LIST OF TABLES 4 LIST OF FIGURES 5 LIST OF ABBREVIATIONS 6 SUMMARY 7 CHAPTERS 1 Philosophy 9 2 Crowdsourced Off-label Medications to Extend ALS Disease Duration 12 Introduction 12 Methodology 15 Results 18 Discussion 25 Tables 33 Figures 38 APPENDIX A: All Table 2 Appearance in Patients and Visits 44 APPENDIX B: All Table 3 Appearance in Patients and Visits 114 REFERENCES 129 3 LIST OF TABLES Page Table 1: Database Overview 33 Table 2: Ontology of Individual Medications 34 Table 3: Ontology of Intervention Groups 36 4 LIST OF FIGURES Page Figure 1: Relational circle
    [Show full text]
  • Commission Implementing Regulation (EU)
    21.3.2013 EN Official Journal of the European Union L 80/1 II (Non-legislative acts) REGULATIONS COMMISSION IMPLEMENTING REGULATION (EU) No 230/2013 of 14 March 2013 on the withdrawal from the market of certain feed additives belonging to the group of flavouring and appetising substances (Text with EEA relevance) THE EUROPEAN COMMISSION, submitted before that deadline for the only animal category for which those feed additives had been auth­ orised pursuant to Directive 70/524/EEC. Having regard to the Treaty on the Functioning of the European Union, (4) For transparency purposes, feed additives for which no applications for authorisation were submitted within the Having regard to Regulation (EC) No 1831/2003 of the period specified in Article 10(2) of Regulation (EC) No European Parliament and of the Council of 22 September 1831/2003 were listed in a separate part of the 2003 on additives for use in animal nutrition ( 1 ), and in Community Register of Feed Additives. particular Article 10(5) thereof, (5) Those feed additives should therefore be withdrawn from Whereas: the market as far as their use as flavouring and appetising substances is concerned, except for animal species and categories of animal species for which applications for (1) Regulation (EC) No 1831/2003 provides for the auth­ authorisation have been submitted. This measure does orisation of additives for use in animal nutrition and not interfere with the use of some of the abovemen­ for the grounds and procedures for granting such auth­ tioned additives according to other animal species or orisation. Article 10 of that Regulation provides for the categories of animal species or to other functional re-evaluation of additives authorised pursuant to Council groups for which they may be allowed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • The Anxiolytic Etifoxine Protects Against Convulsant and Anxiogenic
    Alcohol 43 (2009) 197e206 The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice Marc Verleye*, Isabelle Heulard, Jean-Marie Gillardin Biocodex-De´partement de Pharmacologie-Zac de Mercie`res, Chemin d’Armancourt 60200 Compie`gne, France Received 11 December 2008; received in revised form 3 February 2009; accepted 4 February 2009 Abstract Change in the function of g-aminobutyric acidA (GABAA) receptors attributable to alterations in receptor subunit composition is one of main molecular mechanisms with those affecting the glutamatergic system which accompany prolonged alcohol (ethanol) intake. These changes explain in part the central nervous system hyperexcitability consequently to ethanol administration cessation. Hyperexcitability associated with ethanol withdrawal is expressed by physical signs, such as tremors, convulsions, and heightened anxiety in animal models as well as in humans. The present work investigated the effects of anxiolytic compound etifoxine on ethanol-withdrawal paradigms in a mouse model. The benzodiazepine diazepam was chosen as reference compound. Ethanol was given to NMRI mice by a liquid diet at 3% for 8 days, then at 4% for 7 days. Under these conditions, ethanol blood level ranged between 0.5 and 2 g/L for a daily ethanol intake varying from 24 to 30 g/kg. These parameters permitted the emergence of ethanol-withdrawal symptoms once ethanol administration was terminated. Etifoxine (12.5e25 mg/kg) and diazepam (1e4 mg/kg) injected intraperitoneally 3 h 30 min after ethanol removal, decreased the severity in handling-induced tremors and convulsions in the period of 4e6 h after withdrawal from chronic ethanol treatment.
    [Show full text]
  • Effect of the Gaba Derivative Succicard on the Lipid and Carbohydrate Metabolism in the Offspring of Rats with Experimental Preeclampsia in Early and Late Ontogeny
    ОРИГИНАЛЬНАЯ СТАТЬЯ DOI: 10.19163/2307-9266-2020-8-5-325-335 EFFECT OF THE GABA DERIVATIVE SUCCICARD ON THE LIPID AND CARBOHYDRATE METABOLISM IN THE OFFSPRING OF RATS WITH EXPERIMENTAL PREECLAMPSIA IN EARLY AND LATE ONTOGENY E.A. Muzyko1, V.N. Perfilova1, A.A. Nesterova2, K.V. Suvorin1, I.N. Tyurenkov1 1 Volgograd State Medical University 1, Pavshikh Bortsov Sq., Volgograd, Russia, 400131 2 Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University 11, Kalinin Ave., Pyatigorsk, Russia, 357532 E-mail: [email protected] Received 02 Jan 2019 Accepted 08 Jul 2020 Maternal preeclampsia can bring about metabolic disorders in the offspring at different stages of ontogeny. Up to date, no ways of preventive pharmacological correction of lipid and carbohydrate metabolism disorders developing in different peri- ods of ontogeny in the children born to mothers with this pregnancy complication, have been developed. The aim of the experiment was to study the effect of the gamma-aminobutyric acid derivative succicard (22 mg/kg) and its reference drug pantogam (50 mg) administered per os in the course of treatment in puberty (from 40 to 70 days after birth), on the parameters of lipid and carbohydrate metabolism in the offspring of the rats with experimental preeclampsia, in dif- ferent periods of ontogeny. Materials and methods. To assess the activity of lipid and carbohydrate metabolism in the offspring, an oral glucose toler- ance test was performed at 40 days, 3, 6, 12 and 18 months of age. The level of glycosylated hemoglobin was measured at the age of 6, 12, and 18 months, and the concentrations of total cholesterol, high-density lipoprotein cholesterol and tri- glycerides were tested at 40 days, 3, 6, 12, and 18 months of age.
    [Show full text]
  • Test Items for Licensing Examination Krok 1 PHARMACY
    MINISTRY OF PUBLIC HEALTH OF UKRAINE Department of human resources policy, education and science Testing Board Student ID Last name Variant ________________ Test items for licensing examination Krok 1 PHARMACY (російськомовний варіант) General Instruction Every one of these numbered questions or unfinished statements in this chapter corresponds to answers or statements endings. Choose the answer (finished statements) that fits best and fill in the circle with the corresponding Latin letter on the answer sheet. Authors of items: Abramov A.V., Aleksandrova K.V., Andronov D.Yu., Bilyk O.V., Blinder O.O., Bobyr V.V., Bobrovska O.A., Bohatyriova O.V., Bodnarchuk O.V., Boieva S.S., Bolokhovska T.O., Bondarenko Yu.I., Bratenko M.K., Buchko O.V., Cherneha H.V., Davydova N.V., Deriuhina L.I., Didenko N.O., Dmytriv A.M., Doroshkevych I.O., Dutka N.M., Dynnyk K.V., Filipova L.O., Havryliuk I.M., Herhel T.M., Hlushkova O.M., Hozhdzinsky S.M., Hrekova T.A., Hrechana O.V., Hruzevsky O.A., Hudyvok Ya.S., Hurmak I.S., Ivanets L.M., Ivanov Ye.I., Kartashova T.V., Kava T.V., Kazakova V.V., Kazmirchuk H.V., Kernychna I.Z., Khlus K.M., Khmelnykova L.I., Klebansky Ye.O., Klopotsky H.A., Klymniuk S.I., Kobylinska L.I., Koldunov V.V., Kolesnyk V.P., Kolesnikova T.O., Komlevoy O.M., Kononenko N.M., Kornijevsky Yu.Y., Kremenska L.V., Krushynska T.Yu., Kryzhanovska A.V., Kryshtal M.V., Kukurychkin Ye.R., Kuznietsova N.L., Kuzmina A.V., Lisnycha A.M., Lychko V.H., Makats Ye.F., Maly V.V., Matvijenko A.H., Menchuk K.M., Minarchenko V.M., Mikheiev A.O., Mishchenko
    [Show full text]
  • Etifoxine Impairs Neither Alertness Nor Cognitive Functions of the Elderly: a Randomized, Double-Blind, Placebo-Controlled Crossover Study
    ARTICLE IN PRESS JID: NEUPSY [m6+; June 28, 2018;22:42 ] European Neuropsychopharmacology (2018) 000, 1–8 www.elsevier.com/locate/euroneuro Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study a ,b , ∗ c b D. Deplanque , F. Machuron , N. Waucquier , b b b a E. Jozefowicz , S. Duhem , S. Somers , O. Colin , c a A. Duhamel , R. Bordet a Univ. Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular cognitive disorders, F-59000 Lille, France b Univ. Lille, Inserm, CHU Lille, CIC 1403 - Centre d’Investigation Clinique, F-59000 Lille, France c Univ. Lille, CHU Lille, EA 2694 - Santé publique: épidémiologie et qualité des soins, F-59000 Lille, France Received 22 December 2017; received in revised form 4 May 2018; accepted 17 May 2018 Available online xxx KEYWORDS Abstract Etifoxine; Etifoxine hydrochloride (Stresam ®), a treatment indicated for psychosomatic manifestations of Benzodiazepines; anxiety, could be an alternative to benzodiazepines. While no impact on alertness and cognitive Anxiolytic; functions has been proven among youth, data on elderly are lacking. The primary objective of Cognition; this study was to measure the impact of etifoxine, lorazepam or placebo on alertness in the el- Elderly; derly. The secondary objectives were to evaluate cognitive performances and adverse effects. Geriatric psychiatry In this randomized, placebo-controlled, double-blind, 3-way crossover design, 30 healthy vol- unteers aged 65 to 75 years underwent three one-day sessions. After treatment intake, stan- dardized cognitive tests were conducted using the Cambridge Neuropsychological Test Auto- mated Batteries and other psychological tests (Stroop, Rey Auditory Verbal Learning Test, Digit R Registration: EudraCT 2012-005530-11 and NCT 02147548 ∗ Correspondence to: Department of medical Pharmacology, Faculty of Medicine, 1 place Verdun, 59045 Lille, France.
    [Show full text]
  • Disposition of T Oxic Drugs and Chemicals
    Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • 56 Subpart F—Flavoring Agents and Related Substances
    § 172.510 21 CFR Ch. I (4–1–12 Edition) needed to produce its intended effect (a) They are used in the minimum but not in excess of 13 parts per million quantity required to produce their in- calculated as anhydrous sodium ferro- tended physical or technical effect and cyanide. in accordance with all the principles of [42 FR 14491, Mar. 15, 1977, as amended at 58 good manufacturing practice. FR 17098, Apr. 1, 1993] (b) In the appropriate forms (plant parts, fluid and solid extracts, con- Subpart F—Flavoring Agents and centrates, absolutes, oils, gums, bal- Related Substances sams, resins, oleoresins, waxes, and dis- tillates) they consist of one or more of § 172.510 Natural flavoring substances the following, used alone or in com- and natural substances used in con- bination with flavoring substances and junction with flavors. adjuvants generally recognized as safe Natural flavoring substances and in food, previously sanctioned for such natural adjuvants may be safely used use, or regulated in any section of this in food in accordance with the fol- part. lowing conditions. Common name Scientific name Limitations Aloe ................................................................ Aloe perryi Baker, A. barbadensis Mill., A. ferox Mill., and hybrids of this sp. with A. africana Mill. and A. spicata Baker. Althea root and flowers .................................. Althea officinalis L. Amyris (West Indian sandalwood) ................. Amyris balsamifera L. Angola weed .................................................. Roccella fuciformis
    [Show full text]